AI Article Synopsis

  • The study focused on the effectiveness of liquid biopsies for identifying EGFR mutations in non-small-cell lung cancer (NSCLC) patients treated with EGFR-TKIs.
  • About 59.5% of the 84 patients showed detectable plasma EGFR mutations, with higher rates in those who experienced disease progression.
  • Patients without plasma EGFR mutations had significantly better progression-free survival (PFS) and overall survival (OS) compared to those with mutations, suggesting the importance of monitoring these mutations in treatment outcomes.

Article Abstract

Background: Few trials have evaluated the utility of liquid biopsies to detect epidermal growth factor receptor mutations (EGFRm) at the time of response evaluation and its association with the clinical characteristics and outcomes of non-small-cell lung cancer (NSCLC) patients.

Objective: This study aimed to evaluate, in a real-world clinical setting, the prevalence of plasma EGFRm and its association with the clinical characteristics, response and survival outcomes of NSCLC patients under treatment with EGFR-tyrosine kinase inhibitors (EGFR-TKIs).

Methods: This observational study enrolled advanced or metastatic NSCLC patients, with confirmed tumor EGFRm, receiving treatment with first- or second-generation EGFR-TKIs. Blood samples for the detection of plasma EGFRm were collected at the time of response evaluation and processed using the Target Selector™ assay. The main outcomes were the detection rate of plasma EGFRm, median Progression-Free Survival (PFS) and Overall Survival (OS) according to plasma EGFR mutational status.

Results: Of 84 patients, 50 (59.5%) had an EGFRm detected in plasma. After a median follow-up of 21.1 months, 63 patients (75%) had disease progression. The detection rate of plasma EGFRm was significantly higher in patients with disease progression than in patients with partial response or stable disease (68.3% versus 33.3%; P< 0.01). PFS and OS were significantly longer in patients without plasma EGFRm than among patients with plasma EGFRm (14.3 months [95% CI, 9.25-19.39] vs 11.0 months [95% CI, 8.61-13.46]; P= 0.034) and (67.8 months [95% CI, 39.80-95.94] vs 32.0 months [95% CI, 17.12-46.93]; P= 0.006), respectively. A positive finding in LB was associated with the presence of ⩾ 3 more metastatic sites (P= 0.028), elevated serum carcinoembryonic (CEA) at disease progression (P= 0.015), and an increase in CEA with respect to baseline levels (P= 0.038).

Conclusions: In NSCLC patients receiving EGFR-TKIs, the detection of plasma EGFRm at the time of tumor response evaluation is associated with poor clinical outcomes.

Download full-text PDF

Source
http://dx.doi.org/10.3233/CBM-203164DOI Listing

Publication Analysis

Top Keywords

plasma egfrm
28
nsclc patients
16
response evaluation
12
disease progression
12
plasma
10
patients
10
egfrm
10
plasma egfr
8
outcomes nsclc
8
first- second-generation
8

Similar Publications

Plasma EGFR mutation ctDNA dynamics in patients with advanced EGFR-mutated NSCLC treated with Icotinib: phase 2 multicenter trial result.

Sci Rep

October 2024

Department of Thoracic Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, No. 420 Fuma Road, Jin'an District, 350014, Fuzhou, China.

Plasma epidermal growth factor receptor mutation (EGFRm) circulating tumor DNA (ctDNA) dynamics exhibit promise in predicting outcomes in patients with EGFRm-advanced non-small cell lung cancer (NSCLC). However, there remains limited trial-level data on integrating ctDNA monitoring into clinical practice. We performed a prospective, multicenter trial to investigate the relationship between EGFRm ctDNA dynamic changes and clinical outcomes in NSCLC patients with EGFRm.

View Article and Find Full Text PDF
Article Synopsis
  • The study investigates the challenges of diagnosing and treating leptomeningeal metastases (LM) in patients with EGFR mutation positive non-small cell lung cancer (NSCLC) who are being treated with osimertinib, focusing on identifying resistance mechanisms in cerebrospinal fluid (CSF) and plasma.
  • A group of 28 patients was analyzed, with a high detection rate of the driver mutation in CSF, but resistance mechanisms were found in 27%, indicating limitations in treatment options available at this time.
  • After four weeks on an escalated osimertinib dosage, many patients showed stabilization or worsening of symptoms, suggesting that while some had radiological improvement, overall clinical efficacy remains
View Article and Find Full Text PDF

Purpose: Histologic transformation to small cell lung cancer (SCLC) is a mechanism of treatment resistance in patients with advanced oncogene-driven lung adenocarcinoma (LUAD) that currently requires histologic review for diagnosis. Herein, we sought to develop an epigenomic cell-free DNA (cfDNA)-based approach to noninvasively detect small cell transformation in patients with EGFR mutant (EGFRm) LUAD.

Experimental Design: To characterize the epigenomic landscape of transformed (t)SCLC relative to LUAD and de novo SCLC, we performed chromatin immunoprecipitation sequencing (ChIP-seq) to profile the histone modifications H3K27ac, H3K4me3, and H3K27me3; methylated DNA immunoprecipitation sequencing (MeDIP-seq); assay for transposase-accessible chromatin sequencing; and RNA sequencing on 26 lung cancer patient-derived xenograft (PDX) tumors.

View Article and Find Full Text PDF
Article Synopsis
  • Osimertinib is a targeted therapy for lung adenocarcinoma driven by EGFR mutations, significantly enhancing progression-free survival for patients, though many eventually show disease progression.
  • * An analysis of genetic changes in blood samples from patients undergoing osimertinib treatment revealed frequent PIK3CA/AKT/PTEN mutations, which contribute to resistance against the drug.
  • * Combining osimertinib with the AKT inhibitor capivasertib demonstrates improved effectiveness in overcoming resistance caused by these genetic alterations, offering a new treatment strategy for affected patients.*
View Article and Find Full Text PDF

Introduction: Brain metastases (BM) are common in patients with advanced -mutated (m+) NSCLC. Despite good BM-related outcomes of osimertinib, several patients still experience intracranial progression. A possible explanation is pharmacologic failure due to low plasma trough levels (C) and consequently limited intracranial osimertinib exposure.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!